Table 2. Baseline characteristics of included patients.
| All patients (N = 654) | |
|---|---|
| Sex, n (%) | |
| Male | 318 (48.6) |
| Female | 335 (51.2) |
| Missing | 1 (0.2) |
| Age at start treatment, median years (n (%)) | 5.4 (0.05–18.8) |
| Age at recent evaluation, median years (n (%)) | 12.6 (1.2–35.6) |
| Carboplatin, n (%) | 185 (28.3) |
| Cumulative cisplatin dose, mg/m2 (range) | 400 (55–1600) |
| Cumulative carboplatin dose, mg/mg2 (range) | 1700 (250–9436) |
| Cranial radiotherapy, n (%) | 98 (18.8) |
| Diagnosis, n (%) | |
| Brain tumor | 113 (17.3) |
| Carcinoma | 11 (1.7) |
| Germ cell tumor | 140 (21.4) |
| Lymphoma | 6 (0.9) |
| Neuroblastoma | 128 (19.6) |
| Osteosarcoma | 119 (18.2) |
| Other malignancies | 9 (1.4) |
| Retinoblastoma | 1 (0.2) |
| Rhabdomyosarcoma | 21 (3.2) |
| Soft tissue sarcoma | 2 (0.4) |